MAPK1 and COVID-19: The potential mechanism of action of SFJD for the treatment of COVID-19 is anti-inflammatory, anti-SARS-CoV-2, mainly acting on mitogen-activated protein kinase receptors (MAPK1, MAPK3, MAPK8, MAPK14), interleukin receptors (IL-6, IL-10), TNF, PTGS2, CASP3, and other multiple targets to achieve the therapeutic effect on COVID-19 (119, 120).